Article Text

Download PDFPDF

399 Developing a new targeted therapy for pediatric rhabdomyosarcoma: αvβ3 and HER2 as promising targets for bispecific CAR T-cell therapy
  1. Amanda Lulu,
  2. Joseph Caruso,
  3. Dustin Cobb and
  4. Daniel Lee
  1. University of Virginia, Charlottesville, VA, USA


Background Even though rhabdomyosarcoma (RMS) is the most prevalent sarcoma in children, therapy relies on decades-old, multi-agent chemotherapy, radiation and surgery, which are ineffective in the salvage or metastatic disease setting, with only 30% of patients surviving three years[1]. Therefore, more effective treatments are desperately needed.

Chimeric antigen receptor T-cell (CAR-T) therapy has been highly successful for relapsed/refractory hematologic malignancies, but antigen downregulation by tumors have not uncommonly led to immunotherapy escape across several platforms[2–5]. We hypothesize that simultaneously targeting two RMS antigens with a bispecific CAR-T will provide a new treatment modality while reducing the likelihood of antigen escape. We previously established the efficacy of alpha5beta3 (αvβ3) and HER2 CAR-Ts against diffuse intrinsic pontine glioma/glioblastoma[6] and medulloblastoma[7], respectively. HER2 is known to be expressed on RMS[8], and one child with RMS experienced a temporary remission with HER2-CAR-T[9]. Therefore, targeting αvβ3 and HER2 using a bispecific CAR-T approach may be effective for RMS.

Methods Six alveolar and embryonal RMS cell lines were evaluated by flow cytometry for αvβ3 and HER2 expression. The in vitro kinetics of αvβ3 and HER2-CAR-T killing of RMS were assessed at varying effector-to-target ratios in an xCelligence analyzer, with CD19-CAR and non-transduced T-cells as controls. Antigen-specificity was evaluated by pre-incubating targets with αvβ3/HER2 blocking or control antibodies or by targeting ITGB3 or ERBB2 CRISPR knock out tumor cells. CAR-Ts were then evaluated for changes in activation marker expression by flow cytometry.

Results (1) αvβ3 and/or HER2 are expressed on 6/6 RMS cell lines. Five express both antigens (figure 1A). (2) Separately, αvβ3 and HER2-CAR-Ts rapidly and robustly kill antigenpos RMS in an antigen- and dose-dependent manner. Furthermore, αvβ3 and HER2-CAR-Ts are sensitive, achieving 70% cytolysis at 300 and 1100 targets/cell, respectively (figure 1B) suggesting a lower likelihood of disease escape by antigen down-regulation. (3) Cytolysis is antigen-specific (figure 2). (4) Co-culture of both CARs with RMS drives increased expression of the activation markers CD107a, CD137, CD25, CD69 and PD-1, demonstrating antigen-driven induction of a strong effector response (figure 3).

Conclusions Our data demonstrate that αvβ3 and HER2 are viable RMS targets for a bispecific CAR-T approach. αvβ3 and HER2 CAR-Ts independently control RMS well. They exhibited robust and low-level antigen-specific killing and effector cell activation in vitro, supporting further investigation into their control of RMS in vivo. αvβ3/HER2 bispecific CAR-Ts are being developed, which we expect to perform as well as or better than each CAR independently.

Acknowledgements This work was supported by a V Foundation Scholar Award (DWL), the Childhood Brain Tumor Foundation (DWL), and UVA Strategic Investment Funds (DWL). The authors thank Javed Khan for providing the rhabdomyosarcoma cell lines.


  1. Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MCG, Meyer WH, et al. Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups. J Clin Oncol. 2008;26:2384–9.

  2. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016;375:2561–9.

  3. O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9:eaaa0984.

  4. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439–48.

  5. Dourthe M-E, Rabian F, Yakouben K, Chevillon F, Cabannes-Hamy A, Méchinaud F, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. Nature Publishing Group; 2021;35:3383–93.

  6. Cobb DA, de Rossi J, Liu L, An E, Lee DW. Targeting of the alphav beta3 integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma. J Immunother Cancer. 2022;10:e003816.

  7. Nellan A, Rota C, Majzner R, Lester-McCully CM, Griesinger AM, Mulcahy Levy JM, et al. Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer. 2018;6:30.

  8. Ganti R, Skapek SX, Zhang J, Fuller CE, Wu J, Billups CA, et al. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol Off J U S Can Acad Pathol Inc. 2006;19:1213–20.

  9. Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020;11:3549.

Ethics Approval The study was approved by the University of Virginia’s Institutional Review Board, approval number 18842.

Abstract 399 Figure 1

avß3.28z and HER2.28z CAR-Ts robustly kill antigen+ rhabdomyosarcoma targets even at low effector-to-target ratios. A) RMS cells were analyzed for expression of avß3 and HER2 by flow cytometry. Antigen levels were quantified using BD QuantiBrite Beads. B) CAR-T cell cytolysis was measured via impedance assay in an xCelligence real time cell analyzer against RMS targets. Non-specific CD19 CAR-Ts (negative control) and mock (non-transduced) T-cells were used as controls.

Abstract 399 Figure 2

avß3.28z and HER2.28z CAR-T killing of RMS cells is antigen-specific. A) RH18, B) RH30 and C) RH36 tumor cells were pre-incubated with avß3- or HER2- blocking antibodies or with control IgG antibodies. CAR-Ts were evaluated for tumor cell killing after 12 hours co-culture at 2.5:1 effector:target ratio.

Abstract 399 Figure 3

Higher percentage of CAR-Ts express multiple activation markers with increased antigen expression on tumor cells. Cells were-cocultured for 24 hours at 2.5:1 effector:target ratio and then evaluated by flow cytometry for expression of CD25, CD137 and CD107a. Percentages of CD8+ and CD8- A) avß3.28z and B) HER2.28z CAR-Ts that were positive for 0-3 of the activation markers.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.